Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

Key facts

Study ID

NCT03486067

Run by

Celgene

People needed

183

Starts

2018-04-03

Expected to finish

2025-03-18

Last updated by the study team

2025-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of multiple myeloma with relapsed and refractory disease
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Must have measurable disease as determined by the central laboratory

You may not qualify if…

• Symptomatic central nervous system involvement of multiple myeloma
• Prior autologous stem cell transplant ≤ 3 months prior
• Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
• History of concurrent second cancers requiring active, ongoing systemic treatment
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 105 — Birmingham, Alabama, United States
• Local Institution - 103 — San Francisco, California, United States
• Local Institution - 107 — New Haven, Connecticut, United States
• Local Institution - 106 — Atlanta, Georgia, United States
• Local Institution - 109 — Boston, Massachusetts, United States
• Local Institution - 111 — Boston, Massachusetts, United States
• Henry Ford Medical Center - New Center One — Detroit, Michigan, United States
• Icahn School of Medicine at Mount Sinai Mount Sinai West — New York, New York, United States
• Local Institution - 101 — Seattle, Washington, United States
• Local Institution - 305 — Erlangen, Germany
• Local Institution - 303 — Hamburg, Germany
• Local Institution - 302 — Heidelberg, Germany
• Local Institution - 306 — München, Germany
• Local Institution - 304 — Tübingen, Germany
• Local Institution - 402 — Bergamo, Italy
• Local Institution - 403 — Meldola, Italy
• Local Institution - 401 — Milan, Italy
• Local Institution - 602 — Nagoya, Aichi-ken, Japan
• Local Institution - 603 — Shibuya-ku, Tokyo, Japan
• Local Institution - 605 — Kamakura, Japan
• Local Institution - 604 — Kashiwa, Japan
• Local Institution - 601 — Kyoto, Japan
• Local Institution - 206 — Barcelona, Spain
• Local Institution - 208 — Barcelona, Spain
• Local Institution - 205 — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.